Cost‐of‐illness of atopic dermatitis in Germany: data from dermatology routine care

Progress in the management of atopic dermatitis (AD) and the recent introduction of the first biologic have raised interest in the costs of treating AD.

[1]  A. Tobin,et al.  Psychosocial burden and out‐of‐pocket costs in patients with atopic dermatitis in Ireland , 2020, Clinical and experimental dermatology.

[2]  M. Augustin,et al.  Determinants of costs and benefits in psoriasis routine care: results from a cross‐sectional nationwide study in Germany , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  T. Werfel,et al.  The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis. , 2020, Current opinion in allergy and clinical immunology.

[4]  M. D. de Bruin‐Weller,et al.  Two‐year drug survival of dupilumab in a large cohort of difficult‐to‐treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry , 2020, Allergy.

[5]  L. Rizzo,et al.  Severe atopic dermatitis: Dupilumab is not just safer, but more efficient. , 2020, Allergologia et immunopathologia.

[6]  G. Casazza,et al.  Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience , 2020, Journal of clinical medicine.

[7]  J. Silverberg,et al.  Prevalence of asthma in patients with atopic dermatitis: a systematic review and meta-analysis. , 2020, Journal of the American Academy of Dermatology.

[8]  G. Girolomoni,et al.  The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  S. Ständer,et al.  Characterizing treatment‐related patient needs in atopic eczema: insights for personalized goal orientation , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  M. Augustin,et al.  Atopic dermatitis shows significant cutaneous comorbidity: results from large‐scale investigations in the working population , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  J. Silverberg,et al.  A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  R. Launois,et al.  Importance of out‐of‐pocket costs for adult patients with atopic dermatitis in France , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  M. Ardeleanu,et al.  Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). , 2019, Journal of dermatological science.

[14]  J. Silverberg.  Comorbidities and the impact of atopic dermatitis. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[15]  S. Weidinger,et al.  A critical appraisal and implications of the new National Institute for Health and Care Excellence guideline on dupilumab for treating moderate‐to‐severe atopic eczema , 2019, The British journal of dermatology.

[16]  G. de Carlo,et al.  Out-of-pocket Costs for Individuals with Atopic Eczema: A Cross-sectional Study in Nine European Countries. , 2019, Acta dermato-venereologica.

[17]  M. Augustin,et al.  Review of health economic analyses in atopic dermatitis: how diverse is the literature? , 2018, Expert review of pharmacoeconomics & outcomes research.

[18]  J. Silverberg,et al.  Epidemiology of adult atopic dermatitis. , 2018, Clinics in dermatology.

[19]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[20]  D. Margolis,et al.  Epidemiology of atopic dermatitis in adults: Results from an international survey , 2018, Allergy.

[21]  P. Spuls,et al.  Methotrexate and azathioprine for severe atopic dermatitis: a 5‐year follow‐up study of a randomized controlled trial , 2018, The British journal of dermatology.

[22]  A. Muraro,et al.  Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  A. Wollenberg,et al.  Dupilumab for treatment of atopic dermatitis , 2018, Expert review of clinical pharmacology.

[24]  M. Gooderham,et al.  Dupilumab: A review of its use in the treatment of atopic dermatitis , 2018, Journal of the American Academy of Dermatology.

[25]  K. Reich,et al.  Cost‐of‐illness of psoriasis – results of a German cross‐sectional study , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  T. Agner,et al.  The impact of atopic dermatitis on work life – a systematic review , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  J. Chao,et al.  Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases , 2017, Advances in Therapy.

[28]  E. Simpson.  Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials , 2017, Dermatology and Therapy.

[29]  M. Augustin,et al.  Prevalence and comorbidities in adults with psoriasis compared to atopic eczema , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[30]  S. Nutten.  Atopic Dermatitis: Global Epidemiology and Risk Factors , 2015, Annals of Nutrition and Metabolism.

[31]  J. Ring,et al.  Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[32]  S. Ständer,et al.  Therapeutic Benefits in Atopic Dermatitis Care from the Patients' Perspective: Results of the German National Health Care Study ‘Atopic Health' , 2014, Dermatology.

[33]  N. Klusen,et al.  Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - dritte und aktualisierte Fassung des Hannoveraner Konsens , 2007 .

[34]  Torsten Zuberbier,et al.  Patient perspectives on the management of atopic dermatitis. , 2006, The Journal of allergy and clinical immunology.

[35]  K. Henke,et al.  [Cost of illness studies as a basis for decision making]. , 2006, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.

[36]  J. Ring,et al.  [Cost-of-illness study in patients suffering from atopic eczema in Germany]. , 2005, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[37]  M. Wickman,et al.  The costs of atopy and asthma in children: Assessment of direct costs and their determinants in a birth cohort , 2003, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[38]  A. Ehlers,et al.  Cost evaluation in atopic eczema , 1999 .

[39]  G. Rajka,et al.  Diagnostic Features of Atopic Dermatitis , 1980, Acta Dermato-Venereologica.